Scott Alexander examines the surprisingly broad effects of GLP-1 drugs like Ozempic, exploring their mechanisms and speculating on why they seem to impact so many different conditions. Longer summary

Scott Alexander explores the wide-ranging effects of GLP-1 receptor agonist medications like Ozempic, which are approved for diabetes and obesity but show promise for many other conditions. He delves into the mechanisms behind their effects on diabetes, weight loss, and addiction, speculating on why these drugs seem to have such broad impacts. The post discusses how GLP-1 drugs work in the brain to reduce hunger and dampen reward systems, potentially explaining their effects on addiction. Scott also touches on their anti-inflammatory properties and potential benefits for neurodegenerative diseases, while cautioning that some reported effects may not replicate. Shorter summary

Scott Alexander examines the theory linking inflammation to depression, finding it promising but cautioning against overconfidence, and discusses the potential and limitations of anti-inflammatory drugs as depression treatments. Longer summary

Scott Alexander discusses the theory that depression may be caused by inflammation, reviewing evidence for and against it. He explains how inflammatory cytokines are linked to sickness behavior and depression-like symptoms, and how this theory connects to other known facts about depression. While finding the theory promising, he cautions against overconfidence given past experiences with other depression theories. The post also explores the potential of anti-inflammatory drugs as depression treatments, concluding that while celecoxib shows promise, its cardiovascular side effects make it unsuitable as a first-line treatment for most patients. Shorter summary